Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...

While Kallyope’s drugs are mechanistically unique, the biotech is competing in a crowded space, with other therapies that ...

The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...

In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...